Merck KGaA, Darmstadt, Germany announced that it opened its newly expanded Life Science distribution center in Schnelldorf. The company invested €180 million and added 25,000 square meters in space to the site, nearly doubling its size. It now features a manual down filling operation and additional space for the distribution of products to laboratories and…

Thermo Fisher Scientific announced that it opened a new clinical and commercial ultra-cold facility in the Netherlands. The company aims to expand its clinical trial network in Europe and accelerate the development of advanced therapies. Its new current good manufacturing practice (cGMP) facility in Bleiswijk offers pharmaceutical and biopharma customers tailored, end-to-end support throughout the…

Novo Nordisk’s semaglutide achieved explosive sales in 2023. Ozempic alone generated $13,892 million in sales for the year. But now that Hims & Hers has revealed plans to sell compounded semaglutide to the masses, questions arise about how the Dutch pharma giant will respond. 2023 was a banner year for the firm with its diabetes…

TriLink BioTechnologies today announced it opened its new cGMP mRNA manufacturing facility. The new 32,000 sq. ft. facility, based in San Diego, is specifically designed for mRNA manufacturing. Using the company’s mRNA manufacturing capabilities, it will support late-phase drug developers from Phase 2 to commercialization. TriLink said the opening is expected to help advance the…

Sen-Jam Pharmaceutical this week announced it is partnering with specialty pharmaceutical manufacturer KVK-Tech for formulation and chemistry, manufacturing and controls for anti-inflammatory injectables. The partnership is the third development, manufacturing, distribution and license agreement the pair have signed. The new partnership will further advance Sen-Jam’s first injectable anti-inflammatory therapeutic, SJP-100. Sen-Jam is developing an immunomodulator…

Gilead and Xilio recently announced an exclusive license agreement to develop and commercialize Xilio’s XTX301, a Phase 1 tumor-activated IL-12 program. Waltham, Massachusetts-based Xilio Therapeutics is a clinical-stage biotechnology company that is developing tumor-activated immuno-oncology therapies. It is using a tumor-activated platform to build tumor-activated molecules, including antibodies, cytokines, bispecifics and cell engagers. Each of…

Cardinal Health (NYSE:CAH) this week announced it began construction on its new pharmaceutical distribution center in Columbus, Ohio. The new 350,000 sq ft. logistics center will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products to support the company’s pharmaceutical business. Dublin, Ohio-based Cardinal Health’s Consumer Health Logistics Center will…

Catalent said this week that it reduced its headcount by approximately 300 employees as part of a restructuring effort. The company confirmed the workforce reduction in its 10-Q quarterly report, filed on Feb. 14. This also coincides with preparations for an acquisition as Novo Holdings agreed to buy the leading pharmaceutical CDMO for $16.5 billion…

Reuters reports that a number of big-name drugmakers, including Pfizer, Sanofi and Takeda plan to raise drug prices to start the year. According to the report, the price hikes apply to more than 500 drugs. Excluding different doses and formulations, the reach extends to more than 140 brands of drugs. Reuters said healthcare research firm 3…

Teva’s strategy to boost its operational efficiency and tap strategic partnerships seems to be paying off. In its Q3 earnings report, Teva announced that global revenues were up to $3.9 billion, marking a 7% rise from the previous year’s third quarter. Factors fueling the growth include the robust performance of their specialty medications, Austedo and…